Global Direct-to-Consumer Genetic Testing Market 2017-2021 | Diagnostic Screening Segment Dominates the Global Market | Technavio
Sep. 12, 2018
LONDON--(BUSINESS WIRE)--Sep 12, 2018--According to the latest market research report released by Technavio, the global direct-to-consumer genetic testing market is expected to accelerate at a CAGR of almost 12% during the forecast period. The growing awareness about DTC genetic is one of the key factors triggering the growth of the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180912005843/en/
Technavio has published a new market research report on the global direct to consumer genetic testing market from 2017-2021. (Graphic: Business Wire)
This research report titled ‘ ’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. It also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
The market research analysis categorizes the global direct-to-consumer genetic testing market into the following services:Diagnostic Screening Prenatal, newborn screening, pre-implantation diagnosis Relationship testing
In 2016, the diagnostic screening segment accounted for 65% of the global market. It is mostly conducted to evaluate major treatment decisions. Diagnostic testing helps to identify genes that are responsible for chronic diseases such as cancer.
Global direct-to-consumer genetic testing market: Top emerging trend
Next-generation sequencing and biochip for present and future genetic diagnosis is an emerging trend in the market space. The development of sophisticated technologies such as microarrays, next-generation sequencing, fluorescence in situ hybridization (FISH), and automated DNA sequencing has opened new avenues for cancer biomarkers. These can detect abnormalities in the gene expression and the genetic structure of cancer cells. They can also analyze the changes in DNA, ribonucleic acid (RNA), and chromosomes from the tissue sections of tumors. At present, physicians are focusing on the early detection of cancer. Hence, the adoption of tissue-based biomarkers is increasing. This has led many companies such as Illumina and Roche Diagnostics to focus on the development of next-generation sequencers.
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Technavio’s report provides expert market research on the following topics:
Executive ReportMarket Outline Global Direct-To-Consumer Genetic Testing Market Overview
Market InsightsMarket Sizing and Forecasts Market Growth Market Drivers and Challenges Key Emerging Trends
Market Segmentation AnalysisRegional comparison (APAC, Americas, and EMEA) Key leading countries Market segmentation by service (diagnostic screening, prenatal, newborn screening, pre-implantation diagnosis, and relationship testing) Market segmentation by distribution channel (direct, retail, and laboratory sales)
Vendor LandscapeVendor classification Market positioning of vendors Competitive scenario Analysis of top vendors (23andMe, LabCorp, Myriad Genetics, and Quest Diagnostics)
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180912005843/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: OTHER CONSUMER HEALTH GENETICS ONCOLOGY CONSUMER
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 09/12/2018 12:35 PM/DISC: 09/12/2018 12:35 PM